Tryptamine Therapeutics Limited
TYPTF
$0.015
$0.000.00%
| 12/31/2024 | 09/30/2024 | 02/29/2024 | 11/30/2023 | 08/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 20.18% | -14.24% | -49.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -33.83% | -34.66% | -39.49% |
| Operating Income | -- | -- | 33.83% | 34.66% | 39.49% |
| Income Before Tax | -- | -- | 20.84% | 24.58% | 33.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 20.80% | 24.54% | 33.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 20.80% | 24.54% | 33.47% |
| EBIT | -- | -- | 33.83% | 34.66% | 39.49% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | 23.58% | 34.63% | 52.51% |
| Normalized Basic EPS | -- | -- | 23.78% | 34.69% | 52.54% |
| EPS Diluted | -- | -- | 23.58% | 34.63% | 52.51% |
| Normalized Diluted EPS | -- | -- | 23.78% | 34.69% | 52.54% |
| Average Basic Shares Outstanding | -- | -- | 4.96% | 12.99% | 24.80% |
| Average Diluted Shares Outstanding | -- | -- | 4.96% | 12.99% | 24.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
